Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2020 16:08 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, July 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum to Report Second Quarter 2020 Financial Results and Provide Corporate Update
July 30, 2020 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 29, 2020 16:06 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum Reports First Quarter 2020 Financial Results and Provides Operational Update
May 07, 2020 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
Bellicum’s three GoCAR™ programs remain on track Completed $15 million sale of manufacturing, office and laboratory facility to MD Anderson and entered into supply agreement HOUSTON, May 07, 2020 ...
Bellicum Completes Sale of Houston Facility
April 15, 2020 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
Purchase price of $15 million from sale of manufacturing, office and laboratory facility Current and future GoCAR™ product candidates to be manufactured by MD Anderson HOUSTON, April 15, 2020 ...
Bellicum Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Operational Update
March 12, 2020 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
Presented new Phase 1 translational results for BPX-601 at ASCO GI Initiated new GoCAR-NK™ program targeting BCMA Entered into asset purchase agreement and licensed technology to MD Anderson ...
Bellicum to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update
March 05, 2020 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, March 05, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 28, 2020 16:08 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum Announces Reverse Stock Split
February 05, 2020 12:45 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) (“Bellicum” or the “Company”), a leader in developing novel, controllable cellular immunotherapies for...
Bellicum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 31, 2020 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...